Introduction
============

Most patients with non-small cell lung cancer (NSCLC) are found to have distant metastasis at the time of initial diagnosis.[@b1-cmar-10-3219],[@b2-cmar-10-3219] The American Society of Clinical Oncology Clinical Practice Guideline Update underscores the fact that there is no cure for stage IV NSCLC, but systemic therapy, such as chemotherapy, targeted therapy, and so on, are recommended as the main treatment modalities.[@b3-cmar-10-3219] However, in recent years, due to the improved effect of systemic treatment and further understanding of the concept of "oligometastasis", medical professionals have begun to focus on the role of local therapy in the treatment of NSCLC.[@b4-cmar-10-3219]--[@b7-cmar-10-3219] Notably, the revised eighth edition of TNM classification dictates that a single metastatic lesion in a single distant organ should be included in the new M1b category; whereas multiple lesions in a single organ or multiple lesions in multiple organs should be reclassified as M1c category.[@b8-cmar-10-3219] This revision may determine the possibility of local treatment, such as surgical intervention.

In the present study, we mainly focus on the effect of local surgery on primary sites or regional/distant sites on overall survival (OS) for stage IV NSCLC patients. The Surveillance, Epidemiology, and End Results (SEER) database was used to collect relevant patient data for this analysis.

Methods
=======

Patient selection
-----------------

The SEER database, which includes 18 population-based cancer registries, was used to identify appropriate patient records from a large NSCLC population. The SEER program by the National Cancer Institute provides information on cancer statistics in an effort to reduce the cancer burden among the US population. SEER is supported by the Surveillance Research Program, which provides national leadership in the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based statistics.[@b9-cmar-10-3219] The SEER^\*^Stat 8.3.4 software was used to screen stage IV NSCLC patients with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma treated between 2004 and 2013. Included patients had been microscopically confirmed NSCLC with only 1 primary tumor. Importantly, all included patients had definitive data about survival and surgery available. In addition, patients before 2004 were excluded due to undetailed staging. Finally, patients with lack of clear information on subgroup variables, including age, race, sex, histology, and radiation were also excluded. A flow diagram of the whole selection process is presented in Figure S1.

Personal identifying information is not included in the SEER database so informed consent was not required. Reference number 11561-Nov2016 was used to access the database and this study was approved by the ethics committee of the Shandong Cancer Hospital affiliated with Shandong University.

Statistical analysis
--------------------

OS was regarded as the main study endpoint. Chi-square testing was applied to compare the baseline variables characteristics. The Kaplan--Meier method was used to construct survival curves, and the log-rank test was used to analyze the differences in survival. Univariate and multivariate Cox regression analysis was then used to assess whether surgical intervention was an independent prognostic factor for OS after adjusting for other subgroup variables. Importantly, the effect of local surgery to primary or regional/distant sites on OS using on different subgroup variables, including age, race, sex, histology, stage, and radiation was analyzed by multivariate Cox regression. The resulting statistical information was presented using forest plot. All statistical analyses were performed using SPSS version 22.0 (SPSS, Chicago, IL, USA). All *P*-values were 2-sided and *P*\<0.05 was considered statistically significant.

Results
=======

Patient demographics
--------------------

According to study exclusion and inclusion criteria, a total of 61,418 stage IV NSCLC patients were enrolled. Detailed clinicopathologic features were compared between the patients who underwent surgery and those with no surgical history ([Table 1](#t1-cmar-10-3219){ref-type="table"}). Among these patients, only 11.6% received local surgical treatment. Of patients \<65 years of age, 53.3% received local surgical treatment and 41.1% did not undergo surgical treatment. Most patients were of white racial background (80.6% and 78.1%, respectively) and were diagnosed with adenocarcinoma for 2 groups (71.6% and 68.0%, respectively). Additionally, the percent of patients undergoing surgery was increased by 2% among female and reduced by 2% for male patients compared with those with no surgical history. Importantly, the patients with earlier T and N stage tumors were more likely to receive surgery (52.2% vs 36.0% for T1--2 and 48.5% vs 30.3% for N0--1). Interestingly, 54.8% of patients who underwent surgery also received radiation; whereas only 47.7% of non-surgery patients received radiation. Detailed patient data are presented in [Table 1](#t1-cmar-10-3219){ref-type="table"}.

Effect of surgery on OS
-----------------------

Log-rank testing was used to evaluate survival differences. Specifically, Kaplan--Meier curve analysis showed that NSCLC patients who underwent surgery had better OS (*P*\<0.001); the 5-year survival rate was 11.84% ([Figure 1A](#f1-cmar-10-3219){ref-type="fig"}). Next, patients receiving surgery were divided into the following groups: surgery to primary and to regional/distant sites. Analysis demonstrated that both surgical subgroups all had significant survival benefit compared with patients who did not receive surgery; the 5-year survival rate was 19.15% in surgery to primary sites, and 7.58% in surgery to regional/distant sites (all, *P*\<0.001) ([Figure 1B, C](#f1-cmar-10-3219){ref-type="fig"}). Interestingly, survival benefit was more obvious in patients who received surgery to primary sites than those who received surgery to regional/distant sites (*P*\<0.001) ([Figure 1D](#f1-cmar-10-3219){ref-type="fig"}).

In the next stage of analysis, we adjusted for variables, including age, race, sex, histology, stage T, stage N, and radiation. Multivariate Cox regression was applied to analyze prognostic factors on OS. Results showed that surgery to primary and regional/distant sites were all independent prognostic factors affecting OS (hazard ratio \[HR\]: 2.176; 95% CI: 2.085--2.271; *P*\<0.001 for surgery to primary sites; HR: 1.129; 95% CI: 1.091--1.168; *P*\<0.001 for surgery to regional/distant sites) ([Table 2](#t2-cmar-10-3219){ref-type="table"}).

Subgroup analysis of the relationship between surgery and OS
------------------------------------------------------------

Multivariate Cox regression analysis demonstrated that variables, including age, race, sex, histology, stage T, stage N, and radiation were all independent prognostic factors of OS. To rule out the effects of these variables and further validate the effect of surgery on OS, we conducted the subgroup analysis based on these variables. Remarkably, obvious survival advantage could be observed in the patients who received surgery to primary sites for all the subgroup variables (all, *P*\<0.001) ([Figure 2](#f2-cmar-10-3219){ref-type="fig"}). Importantly, patients with surgery to primary sites with stage N0 showed the most significant OS benefit (HR: 0.388; 95% CI: 0.363--0.415, *P*\<0.001); the patients with N3 also showed the significant OS benefit (HR: 0.736; 95% CI: 0.631--0.857, *P*\<0.001) ([Figure 2](#f2-cmar-10-3219){ref-type="fig"}).

Next, we analyzed the effect of surgery to regional/distant sites on OS taking into account different variables. Survival benefit was not found in patients with surgery to regional/distant sites who were of black racial background, or had either stage N1 squamous cell carcinoma, large cell carcinoma of (black: HR: 0.937; 95% CI: 0.852--1.031, *P*=0.181; squamous cell carcinoma: HR: 0.965; 95% CI: 0.895--1.041, *P*=0.361; large cell carcinoma: HR: 0.977; 95% CI: 0.857--1.113, *P*=0.725; stage N1: HR: 0.961; 95% CI: 0.859--1.076, *P*=0.490) ([Figure 3](#f3-cmar-10-3219){ref-type="fig"}). Survival benefit was observed among patients with surgery to regional/distant sites in other subgroup variables (all, *P*\<0.01) ([Figure 3](#f3-cmar-10-3219){ref-type="fig"}).

Discussion
==========

This study was focused on the effect of surgery on survival in stage IV NSCLC patients. Three interesting clinical findings were demonstrated and will be discussed as follows: local surgery might be an option for stage IV NSCLC patients; surgery to primary sites had better survival benefit compared with patients undergoing surgery at regional/distant tumor sites; and finally, patients with stage N0 may be more suited to receive surgery to primary sites.

Previously, there has not been sufficient evidence on the role of surgery therapy for stage IV NSCLC patients. Some oncologists have focused on this key clinical issue but the issue remains controversial. A single-center study performed in China demonstrated that surgical treatment of M1a NSCLC was associated with improved survival compared with published reports and could be considered in the management of selected cases.[@b10-cmar-10-3219] In addition, some studies have shown that selected patients who undergo surgical resection for a primary tumor and receive effective local therapy for metastatic lesions still have a chance to obtain long-term survival. Further studies should focus on the possible use of surgery as a strategy for therapeutic "consolidation" in appropriately selected patients with stage IV NSCLC receiving combined modality care.[@b11-cmar-10-3219],[@b12-cmar-10-3219] Another study from Duke University Medical Center demonstrated that surgery for cT1--2, N0--1, M1 or cT3, N0, M1 NSCLC tumors is associated with a 5-year survival of 25% and does not appear to compromise outcomes when compared with non-operative therapy.[@b13-cmar-10-3219] Consistent with these results, the present study showed that OS benefit was observed in NSCLC patients who received surgery therapy. Notably, we found that patients who received surgery only to primary sites had better survival prognosis than those who received surgery to regional/distant sites. In fact, few studies have compared survival of patients with only surgery to primary sites vs regional/distant sites.

Several studies have demonstrated that pulmonary resection could bring reasonable long-term survival benefit for patients with oligometastases disease, such as single adrenal or brain metastasis.[@b14-cmar-10-3219]--[@b17-cmar-10-3219] It should be noted that these studies were based on small sample sizes; however, similar results were validated in this present study based on a large sample size. Some studies also demonstrated that surgical resection of distant sites, including brain, liver, adrenal gland, and other sites could improve the survival rates for such patients.[@b18-cmar-10-3219]--[@b20-cmar-10-3219] Interestingly, some studies have demonstrated that some select patients may benefit from surgical treatment of both the primary and metastasis sites.[@b21-cmar-10-3219],[@b22-cmar-10-3219] In the present study, survival benefit was also found in patients who received surgery to primary and metastasis sites. However, an obvious difference was not found between the patients with surgery to primary/regional/distant sites and those with surgery only to primary tumor sites; therefore, it is still important to study the proper determination of operation sites in for stage IV NSCLC patients.

A review by Novoa et al found that an absence of mediastinal lymph node involvement is a positive predictor of surgery outcomes for stage IV NSCLC patients.[@b23-cmar-10-3219] In fact, metastatic N0 NSCLC patients had a favorable prognosis and a lower ratio of adrenal gland metastasis than those with clinical N1--three disease.[@b24-cmar-10-3219] In this study, we found that patients with stage N0 are more likely to benefit from surgery. Several other studies support these findings. Billing et al demonstrated that the presence of thoracic lymph node metastases (N1 or N2) significantly affected 5-year survival (*P*=0.001), and surgical resection may prove beneficial in a selected group of patients with synchronous brain metastases and lung cancer without lymph node metastases.[@b25-cmar-10-3219] Also, David et al showed that surgical resection of NSCLC can result in a 5-year survival rate of 30%--50%, but this figure is heavily influenced by the presence of mediastinal nodal disease, a factor, which must be evaluated before selection for surgery.[@b12-cmar-10-3219] Taking into account these results, surgical intervention would bring more benefit to patients with stage N0 NSCLC.

Several limitations should be noted in this study. First, we cannot avoid the impact of selection bias on some baseline variables in this retrospective study, despite the relatively rather large sample size. Second, in multivariate Cox regression analysis, we only analyzed radiation therapy. The other therapy information, including chemotherapy, molecule-targeted therapy, and exact surgical types were not entered in our present study due to the limitations of the SEER database itself. Finally, a study by Hanagiri et al demonstrated that surgical treatment for NSCLC with oligometastatic disease should be considered to be one arm of multidisciplinary treatment.[@b11-cmar-10-3219] Some studies also showed that other variables, including good performance status and nonsmoking histology may predict for improved survival in such patients.[@b10-cmar-10-3219] However, also due to the data limitations of the SEER database, these variables, including good performance status, nonsmoking histology, and the oligometastatic variables were not able to be analyzed in this study.

Conclusion
==========

Our results showed that selected stage IV NSCLC patients may benefit from surgery of primary tumor sites. Patients especially with stage N0 tumors should be recommended to undergo operation. Multi-institutional trials are warranted to further validate our conclusions and determine the most suitable patients for surgery.
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======================
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Data filter flow chart based on SEER database.
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![Kaplan--Meier curves verified by log-rank test.\
**Notes:** (**A**) Difference in OS between patients who received surgery vs no surgery (*P*\<0.001). (**B**) Difference in OS between patients who received surgery to primary sites vs no surgery (*P*\<0.001). (**C**) Difference in OS between patients who received surgery to regional/distant sites vs no surgery (*P*\<0.001). (**D**) Difference in OS between patients who received surgery combination vs no surgery (*P*\<0.001).\
**Abbreviation:** OS, overall survival.](cmar-10-3219Fig1){#f1-cmar-10-3219}

![The effect of primary site surgery on OS based on different subgroup variables.\
**Notes:** Findings were verified by Cox proportional hazard analysis and presented as a forest plot.\
**Abbreviations:** OS, overall survival; Ad, adenocarcinoma; Sq, squamous; La, large cell carcinoma.](cmar-10-3219Fig2){#f2-cmar-10-3219}

![The effect of regional/distant site surgery on OS based on different subgroup variables.\
**Notes:** Findings were verified by Cox proportional hazard analysis and presented as a forest plot.\
**Abbreviations:** OS, overall survival; Ad, adenocarcinoma; Sq, squamous; La, large cell carcinoma.](cmar-10-3219Fig3){#f3-cmar-10-3219}

###### 

Characteristics of NSCLC with AJCC stage IV extracted from SEER Database

  Variables              Surgery (%)    No surgery (%)   *P*-value
  ---------------------- -------------- ---------------- -----------
  **Age (years)**                                        \<0.001
  \<65                   3,807 (53.3)   22,314 (41.1)    
  ≥65                    3,330 (46.7)   31,967 (58.9)    
  **Race**                                               \<0.001
  White                  5,756 (80.6)   42,387 (78.1)    
  Black                  875 (12.3)     7,064 (13.0)     
  Others                 506 (7.1)      4,830 (8.9)      
  **Sex**                                                \<0.001
  Female                 3,306 (46.3)   24,062 (44.3)    
  Male                   3,831 (53.7)   30,219 (55.7)    
  **Histology**                                          \<0.001
  Adenocarcinoma         5,112 (71.6)   36,894 (68.0)    
  Squamous               1,587 (22.2)   14,953 (27.5)    
  Large cell carcinoma   438 (6.1)      2,434 (4.5)      
  **T stage**                                            \<0.001
  T1                     1,385 (19.4)   5,652 (10.4)     
  T2                     2,342 (32.8)   13,918 (25.6)    
  T3                     455 (6.4)      3,385 (6.2)      
  T4                     2,955 (41.4)   31,326 (57.7)    
  **N stage**                                            \<0.001
  N0                     2,620 (36.7)   12,212 (22.5)    
  N1                     844 (11.8)     4,216 (7.8)      
  N2                     2,771 (38.8)   26,598 (49.0)    
  N3                     902 (12.6)     11,255 (20.7)    
  **Radiation**                                          \<0.001
  Yes                    3,912 (54.8)   25,901 (47.7)    
  No                     3,225 (45.2)   28,380 (52.3)    

**Abbreviations:** AJCC, American Joint Committee on Cancer; NSCLC, non-small cell lung cancer; SEER, Surveillance Epidemiology and End Results.

###### 

The effect of different subgroup variables on OS for NSCLC with AJCC stage IV analyzed by Cox proportional hazard model

  Variables                      Univariate analysis   Multivariate analysis                          
  ------------------------------ --------------------- ----------------------- ---------------------- ---------
  **Surgery to primary sites**   1271.84               \<0.001                                        \<0.001
  Yes                                                                          Reference              
  No                                                                           2.176 (2.085--2.271)   \<0.001
  **Surgery to other sites**     47.54                 \<0.001                                        \<0.001
  Yes                                                                          Reference              
  No                                                                           1.129 (1.091--1.168)   \<0.001
  **Age (years)**                562.98                \<0.001                                        \<0.001
  \<65                                                                         Reference              
  ≥65                                                                          1.240 (1.218--1.262)   \<0.001
  **Race**                       421.29                \<0.001                                        \<0.001
  White                                                                        Reference              
  Black                                                                        1.015 (0.989--1.041)   0.259
  Others                                                                       0.718 (0.696--0.742)   \<0.001
  **Sex**                        437.92                \<0.001                                        \<0.001
  Female                                                                       Reference              
  Male                                                                         1.204 (1.183--1.225)   \<0.001
  **Histology**                  267.30                \<0.001                                        \<0.001
  Adenocarcinoma                                                               Reference              
  Squamous                                                                     1.130 (1.108--1.153)   \<0.001
  Large cell carcinoma                                                         1.289 (1.240--1.341)   \<0.001
  **T stage**                    739.26                \<0.001                                        \<0.001
  T1                                                                           Reference              
  T2                                                                           1.171 (1.135--1.208)   \<0.001
  T3                                                                           1.338 (1.282--1.397)   \<0.001
  T4                                                                           1.417 (1.377--1.459)   \<0.001
  **N stage**                    230.40                \<0.001                                        \<0.001
  N0                                                                           Reference              
  N1                                                                           1.092 (1.055--1.131)   \<0.001
  N2                                                                           1.182 (1.156--1.208)   \<0.001
  N3                                                                           1.143 (1.113--1.174)   \<0.001
  **Radiation**                  92.23                 \<0.001                                        \<0.001
  Yes                                                                          Reference              
  No                                                                           1.089 (1.070--1.108)   \<0.001

**Abbreviations:** AJCC, American Joint Committee on Cancer; NSCLC, non-small cell lung cancer; OS, overall survival.
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